Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Jun;23(6):693-695.
doi: 10.1016/S1470-2045(22)00252-2. Epub 2022 May 23.

COVID-19 vaccine effectiveness in patients with cancer: remaining vulnerabilities and uncertainties

Nicole M Kuderer  1 , Gary H Lyman  2
Affiliations
Comment

COVID-19 vaccine effectiveness in patients with cancer: remaining vulnerabilities and uncertainties

Nicole M Kuderer et al. Lancet Oncol. 2022 Jun.
No abstract available

PubMed Disclaimer

Conflict of interest statement

NMK reports consulting fees from Beyond Spring, Bristol Myers Squibb, G1 Therapeutics, Sandoz, Seattle Genetics, Janssen, Pfizer, and Spectrum and research funding from Amgen to her institution (family member), all outside the submitted Comment. GHL reports research grant support from Amgen to the Fred Hutchinson Cancer Center and consulting fees from Beyond Spring, G1 Therapeutics, Partner Therapeutics, Samsung Bioepis, Merck, Jazz, TEVA, Squibb, Sandoz, Seattle Genetics, and Fresenius Kabi, all outside the submitted Comment.

Comment on

  • Vaccine effectiveness against COVID-19 breakthrough infections in patients with cancer (UKCCEP): a population-based test-negative case-control study.
    Lee LYW, Starkey T, Ionescu MC, Little M, Tilby M, Tripathy AR, Mckenzie HS, Al-Hajji Y, Barnard M, Benny L, Burnett A, Cattell EL, Charman J, Clark JJ, Khan S, Ghafoor Q, Illsley G, Harper-Wynne C, Hattersley RJ, Lee AJX, Leonard PC, Liu JKH; NCRI Consumer Forum; Pang M, Pascoe JS, Platt JR, Potter VA, Randle A, Rigg AS, Robinson TM, Roques TW, Roux RL, Rozmanowski S, Tuthill MH, Watts I, Williams S, Iveson T, Lee SM, Middleton G, Middleton M, Protheroe A, Fittall MW, Fowler T, Johnson P. Lee LYW, et al. Lancet Oncol. 2022 Jun;23(6):748-757. doi: 10.1016/S1470-2045(22)00202-9. Epub 2022 May 23. Lancet Oncol. 2022. PMID: 35617989 Free PMC article.

References

    1. Kuderer NM, Choueiri TK, Shah DP, et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet. 2020;395:1907–1918. - PMC - PubMed
    1. Clift AK, Coupland CAC, Keogh RH, et al. Living risk prediction algorithm (QCOVID) for risk of hospital admission and mortality from coronavirus 19 in adults: national derivation and validation cohort study. BMJ. 2020;371 - PMC - PubMed
    1. Grivas P, Khaki AR, Wise-Draper TM, et al. Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium. Ann Oncol. 2021;32:787–800. - PMC - PubMed
    1. Fendler A, de Vries EGE, GeurtsvanKessel CH, et al. COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety. Nat Rev Clin Oncol. 2022 doi: 10.1038/S41571-022-00610-8. published online March 11. - DOI - PMC - PubMed
    1. Wu JT, La J, Branch-Elliman W, et al. Association of COVID-19 vaccination with SARS-CoV-2 infection in patients with cancer: a US nationwide veterans affairs study. JAMA Oncol. 2022;8:281–286. - PMC - PubMed

Substances